BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/29/2014 6:53:00 PM | Browse: 887 | Download: 657
Publication Name World Journal of Clinical Cases
Manuscript ID 1794
Country Italy
Received
2013-01-07 08:56
Peer-Review Started
2013-01-07 16:31
To Make the First Decision
2013-01-17 11:06
Return for Revision
2013-02-04 18:47
Revised
2013-02-18 01:13
Second Decision
2013-03-28 17:25
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2013-03-29 11:55
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
2013-04-04 01:44
Typeset the Manuscript
2013-05-14 21:51
Publish the Manuscript Online
2013-05-16 14:52
ISSN 2307-8960 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Minireviews
Article Title Biological therapy for dermatological manifestations of inflammatory bowel disease
Manuscript Source Invited Manuscript
All Author List Maddalena Zippi, Roberta Pica, Daniela De Nitto and Paolo Paoluzi
Funding Agency and Grant Number
Corresponding Author Maddalena Zippi, MD, Unit of Gastroenterology and Digestive Endoscopy, Sandro Pertini Hospital, Via dei Monti Tiburtini 385, 00157 Rome, Italy. maddyzip@yahoo.it
Key Words Biological therapies; Erythema nodosum; Inflammatory bowel disease; Psoriasis; Pyoderma gangrenosum
Core Tip Ulcerative colitis and Crohn’s disease are the best known forms of inflammatory bowel disease (IBD) and are considered immune-mediated disorders of unknown etiology that primarily affect the gastrointestinal tract. In addition, other organ systems can be involved, such as skin. Erythema nodosum, pyoderma gangrenosum and psoriasis are the dermatological comorbidities often associated with it. The anti-tumor necrosis factor (TNF)-α drugs (infliximab and adalimumab) have significantly changed the management of these conditions. In this brief review, we provide an overview on the prevalence and clinical aspects of the more commonly reported skin manifestations of IBD and the role of TNF-α inhibitors in their treatment.
Publish Date 2013-05-16 14:52
Citation Zippi M, Pica R, De Nitto D, Paoluzi P. Biological therapy for dermatological manifestations of inflammatory bowel disease. World J Clin Cases 2013; 1(2): 74-78
URL http://www.wjgnet.com/2307-8960/full/v1/i2/74.htm
DOI http://dx.doi.org/10.12998/wjcc.v1.i2.74
Full Article (PDF) WJCC-1-74.pdf
Manuscript File 1794-Review.doc
Answering Reviewers 1794-Answering reviewers.doc
Copyright License Agreement 1794-Copyright assignment.doc
Peer-review Report 1794-Peer review(s).pdf
Scientific Editor Work List 1794-Scientific editor work list.doc